Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q1 FY20 results · Apr–Jun 2019
Natco Pharma reported revenue from operations of ₹492.30 crore (down 8.6% from Q1 FY19) and net profit of ₹142.80 crore (down 21.1% from Q1 FY19) for Q1 FY20 (Apr–Jun 2019), on a consolidated basis.
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 492.30 | 538.60 | −8.6% | 455.70 | +8.0% |
| Other income | 21.00 | 35.90 | −41.5% | 31.00 | −32.3% |
| Total income | 513.30 | 574.50 | −10.7% | 486.70 | +5.5% |
| Profit before tax | 183.80 | 232.30 | −20.9% | 152.40 | +20.6% |
| Net profit for the period | 142.80 | 181.10 | −21.1% | 120.40 | +18.6% |
| Attributable to shareholders of the company | 143.20 | 181.60 | −21.1% | 120.80 | +18.5% |
| EPS, basic (₹) | 7.87 | 9.84 | −20.0% | 6.59 | +19.4% |
| Net margin (%) | 29.0 | 33.6 | 26.4 |
| Item | Q1 FY20 | Q1 FY19 | YoY | Q4 FY19 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 464.70 | 515.70 | −9.9% | 416.30 | +11.6% |
| Other income | 20.40 | 35.70 | −42.9% | 30.70 | −33.6% |
| Total income | 485.10 | 551.40 | −12.0% | 447.00 | +8.5% |
| Profit before tax | 188.30 | 239.80 | −21.5% | 154.40 | +22.0% |
| Net profit for the period | 147.70 | 188.60 | −21.7% | 123.40 | +19.7% |
| EPS, basic (₹) | 8.11 | 10.22 | −20.6% | 6.73 | +20.5% |
| Net margin (%) | 31.8 | 36.6 | 29.6 |
Consolidated
- Filed with BSE
- 10 Aug 2019, 09:18 IST
- Board meeting
- 09 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Aug 2019, 09:18 IST
- Board meeting
- 09 Aug 2019
- Period
- 01 Apr 2019 to 30 Jun 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE